Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVEONASDAQ:BLCMNASDAQ:SCPHNASDAQ:SESN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsBLCMBellicum Pharmaceuticals$0.07$0.08$0.06▼$1.31$727K1.3922,874 shs6,059 shsSCPHscPharmaceuticals$3.97-1.7%$3.44$1.94▼$5.65$209.58M0.38374,431 shs184,541 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SCPHscPharmaceuticals0.00%+2.58%-5.48%+70.39%-9.98%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASCPHscPharmaceuticals4.1452 of 5 stars3.54.00.04.20.61.70.6SESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO Pharmaceuticals 0.00N/AN/AN/ABLCMBellicum Pharmaceuticals 0.00N/AN/AN/ASCPHscPharmaceuticals 3.00Buy$14.00252.64% UpsideSESNSesen Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28BLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33SCPHscPharmaceuticals$36.33M5.77N/AN/A$0.27 per share14.70SESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/ABLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ASCPHscPharmaceuticals-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)SESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ALatest AVEO, BLCM, SESN, and SCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35BLCMBellicum PharmaceuticalsN/A3.043.04SCPHscPharmaceuticals3.865.484.61SESNSesen BioN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%BLCMBellicum Pharmaceuticals4.93%SCPHscPharmaceuticals89.52%SESNSesen Bio16.45%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%BLCMBellicum Pharmaceuticals10.30%SCPHscPharmaceuticals4.78%SESNSesen Bio3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableSCPHscPharmaceuticals3052.79 million50.27 millionOptionableSESNSesen Bio35203.49 million196.98 millionOptionableAVEO, BLCM, SESN, and SCPH HeadlinesRecent News About These CompaniesTrey MewesApril 9, 2024 | startribune.comSDevin Haney: biography, record, fights and moreDecember 9, 2023 | espn.comTyson Fury: Biography, record, fights and moreDecember 2, 2023 | espn.comWhy the Tucker Carlson Biography Sales Are So PatheticSeptember 13, 2023 | thedailybeast.comTSesen Bio (NASDAQ: SESN)August 4, 2023 | fool.comJames McTeigue Biography & MoviesMay 10, 2023 | tribute.caTAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen BioMarch 6, 2023 | bizjournals.comSesen Bio wins shareholder approval for Carisma mergerMarch 2, 2023 | msn.comSesen Bio Stockholders Approve Merger with Carisma TherapeuticsMarch 2, 2023 | finance.yahoo.comSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsFebruary 28, 2023 | finance.yahoo.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing InvestigationsFebruary 24, 2023 | benzinga.comLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With CarismaFebruary 21, 2023 | finance.yahoo.comBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 17, 2023 | stockhouse.comLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingFebruary 16, 2023 | businesswire.comSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerFebruary 16, 2023 | finance.yahoo.comSesen Bio reaches deal with investor group, paving way for Carisma mergerFebruary 15, 2023 | endpts.comELatest terms of Sesen Bio and Carisma merger appear to pass musterFebruary 15, 2023 | thepharmaletter.comT5 big dividend moves: Group 1 Automotive hikes by 20% | Pro RecapFebruary 15, 2023 | finance.yahoo.comBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 15, 2023 | finance.yahoo.comSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupFebruary 14, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVEO, BLCM, SESN, and SCPH Company DescriptionsAVEO Pharmaceuticals NASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Bellicum Pharmaceuticals NASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.scPharmaceuticals NASDAQ:SCPH$3.97 -0.07 (-1.73%) As of 07/3/2025 01:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Sesen Bio NASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.